All Blogs
Mar 19, 2026
MiniMed Secures FDA Clearance for MiniMed Flex; Spinal Elements Expands Portfolio with FDA-Cleared Ventana® Platform and Initial ALIF Launch; Mindray North America Strengthens Respiratory Care Offering Through Ventilator Market Entry; Micro-Tech Endoscopy Enters Definitive Deal to Acquire Key GI Product Lines from CONMED; Composite Manufacturing Inc. Unveils Study Showing NekSpine® Exoskeleton Eases Neck and Back Load During Simulated Surgeries; SkinVision Partners on Landmark Trial to Expand Dermatology Care Access in the U.S.
MiniMed Announced the FDA Clearance of MiniMed Flex™, the Company's Smallest Insulin Pump Featuring its First Smartphone-Controlled Design On 18 March 2026, MiniMed announced that it had received clearance from the U.S. Food and Drug Administration (FDA) for its MiniMed Flex™, a next-generation, discreet i...
Read More...
Mar 18, 2026
Defibrillators at the Heart of Cardiac Care: Challenges, Innovations, and the Road Ahead
Defibrillators are critical medical devices designed to correct life-threatening cardiac arrhythmias, particularly ventricular fibrillation and ventricular tachycardia, which can rapidly lead to sudden cardiac arrest (SCA). By delivering a controlled electrical shock to the heart, defibrillators aim to restore a no...
Read More...
Mar 17, 2026
Sana Biotechnology Reveals Long-Term Positive Data from Type 1 Diabetes Islet Cell Transplant Trial; Bayer’s Finerenone Demonstrates Efficacy in Phase III FIND-CKD Study in Non-Diabetic CKD Population; Immutep Halts Phase III NSCLC Trial; REGENXBIO’s RGX-202 Demonstrates Promising Interim Results in Phase I/II AFFINITY DUCHENNE Trial; Ultragenyx’s DTX301 Gene Therapy Delivers Positive 36-Week Phase 3 Data
Sana Biotechnology Reports Sustained Positive 14-Month Results from Type 1 Diabetes Islet Cell Transplant Study Without Immunosuppression Sana Biotechnology reported continued positive clinical results from its cell therapy programs, reinforcing its broader strategy of developing engineered cells as medicines. T...
Read More...
Mar 16, 2026
The Underactive Bladder Syndrome Treatment Landscape: Few Contenders, High Unmet Need
Summary The current treatment landscape for underactive bladder largely depends on pharmacological management and catheterization. Despite the significant unmet need, the clinical development pipeline for UAB remains relatively sparse. Notable candidates include TAC-302, being developed by Taiho Pharmace...
Read More...
Mar 13, 2026
SOTYKTU Expands Its Reach as Bristol Myers Squibb Lands Key Approval in Psoriatic Arthritis
Summary Bristol Myers Squibb’s SOTYKTU has received FDA approval for adults with active psoriatic arthritis, becoming the first and only TYK2 inhibitor authorized for this indication. The drug extends its reach beyond its 2022 approval for moderate-to-severe plaque psoriasis, reinforcing BMS’s bid to b...
Read More...
Mar 12, 2026
QT Imaging Secures FDA Clearance for Enhanced Breast Acoustic CT Scanner Configuration; LifeVac Secures FDA Authorization as the First and Only Anti-Choking Device; Smith+Nephew Introduces Next-Generation ALLEVYN COMPLETE CARE Foam Dressing for Enhanced Wound Management; Olympus Corporation Debuts Next-Gen Surgical Visualization Platform in the U.S.; IceCure Medical Receives FDA Approval for Post-Marketing ‘CHOICE’ Study of ProSense Cryoablation System; Envoy Medical Concludes Enrollment for Landmark Trial of Fully Implanted Cochlear Implant
QT Imaging Received FDA Clearance for its Breast Acoustic CT Scanner Enhanced Configuration to Improve Posterior Breast Imaging Coverage On 10 March 2026, QT Imaging Holdings, Inc., a medical device company focused on advancing breast health management through innovative radiation-free imaging technology, ...
Read More...
Mar 11, 2026
Companion Diagnostics in Healthcare: Powering the Era of Precision Medicine
The landscape of modern medicine is undergoing a profound shift from a "one-size-fits-all" approach to a model that is deeply personalized and data-driven. At the heart of this transformation is the concept of precision medicine, which seeks to tailor medical treatment to the individual characteristics of each pati...
Read More...
Mar 10, 2026
Roche Reveals Update from Phase III persevERA Study Targeting ER-Positive Advanced Breast Cancer; Ipsen Confirms Voluntary Withdrawal of TAZVERIK for Select Oncology Indications; Bristol Myers Squibb Unveils Positive Phase 3 Data from SUCCESSOR-2 Study Evaluating Mezigdomide in R/R Multiple Myeloma; Servier Announces Acquisition of Day One Biopharmaceuticals to Bolster Rare Cancer Portfolio; Pfizer Advances Trispecific Antibody with Positive Phase 2 Results in Atopic Dermatitis
Roche Announces Latest Findings from Phase III persevERA Study in ER-Positive Advanced Breast Cancer Roche announced results from the Phase III persevERA Breast Cancer study evaluating the investigational oral selective estrogen receptor degrader (SERD) giredestrant in combination with the CDK4/6 inhibitor palbo...
Read More...
Mar 09, 2026
Radioligand Therapies: A Rapidly Emerging Pillar in the Oncology Market
Summary Radioligand therapy is becoming a crucial component of cancer treatment. Approved radioligand therapy includes LUTATHERA (for GEP-NETs), XOFIGO, PLUVICTO (both for prostate cancer), and ZEVALIN (for follicular B-cell non-Hodgkin's lymphoma). Leading companies such as Novartis, Curium Pharma,...
Read More...
Mar 06, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Summary Iovance’s AMTAGVI has become the first personalized TIL therapy to receive regulatory clearance, gaining accelerated FDA approval for use in advanced melanoma following PD-1 inhibitor treatment. AMTAGVI approval has sparked intensified activity across the field, with companies such as Obsidian Therap...
Read More...